share_log

賽生藥業：根據《收購守則》規則22作出的交易披露

SCICLONE PHARMA: Disclosure of Dealings under Rule 22 of the Takeovers Code

Hong Kong Stock Exchange ·  Apr 18 04:38
Summary by Moomoo AI
赛生药业控股有限公司於2024年4月17日宣布，根據香港《公司收購及合併守則》規則22，執行人員林惠斌透過協議安排進行了股份交易。林惠斌於2024年4月5日根據公司首次公開發售後受限股份單位計劃，獲得10,000股股份獎勵，並於同日以每股0.0000港元的價格買入該批股份。該交易後，林惠斌持有的赛生药业股份總數達到19,967股，佔公司已發行股份的0.0032%。
赛生药业控股有限公司於2024年4月17日宣布，根據香港《公司收購及合併守則》規則22，執行人員林惠斌透過協議安排進行了股份交易。林惠斌於2024年4月5日根據公司首次公開發售後受限股份單位計劃，獲得10,000股股份獎勵，並於同日以每股0.0000港元的價格買入該批股份。該交易後，林惠斌持有的赛生药业股份總數達到19,967股，佔公司已發行股份的0.0032%。
SAI SANG PHARMACEUTICAL HOLDINGS LIMITED ANNOUNCED ON 17 APRIL 2024 THAT UNDER RULE 22 OF THE HONG KONG CODE OF COMPANY ACQUISITIONS AND MERGERS, ITS EXECUTIVE OFFICER LIN HUI-BIN HAS ENTERED INTO A SHARE TRANSACTION THROUGH AN AGREED ARRANGEMENT. On April 5, 2024, Lin received a 10,000 share bonus under the company's initial public offering restricted share plan and purchased the lot at HK$0.0000 per share on the same day. After the transaction, the total number of shares in Sai Seng Pharmaceuticals held by Lin reached 19,967 shares, representing 0.0032% of the company's issued shares.
SAI SANG PHARMACEUTICAL HOLDINGS LIMITED ANNOUNCED ON 17 APRIL 2024 THAT UNDER RULE 22 OF THE HONG KONG CODE OF COMPANY ACQUISITIONS AND MERGERS, ITS EXECUTIVE OFFICER LIN HUI-BIN HAS ENTERED INTO A SHARE TRANSACTION THROUGH AN AGREED ARRANGEMENT. On April 5, 2024, Lin received a 10,000 share bonus under the company's initial public offering restricted share plan and purchased the lot at HK$0.0000 per share on the same day. After the transaction, the total number of shares in Sai Seng Pharmaceuticals held by Lin reached 19,967 shares, representing 0.0032% of the company's issued shares.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more